FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4315702793> ?p ?o ?g. }

• W4315702793 abstract "Abstract Background The difficulty of CD19 CAR-T cells entering solid tumors is one of the reasons for its poor efficacy in the treatment of lymphoma.The chemokine CXCL13 secreted by stromal cells of the lymph nodes, induces the homing of B and T lymphocytes who express its receptor CXCR5. Pre-clinical trials have shown that CD19 CAR-T cells expressing CXCR5 could increase its migration to the tumor microenvironment and enhance the anti-tumor function of CD19 CAR-T cells. Methods We generated a novel anti-CD19 CAR-expressing CXCR5 protein. Then, we conducted a phase I clinical trial to evaluate safety and efficacy of CXCR5 CD19 CAR-T cells in the treatment of relapsed or refractory (R/R) B-cell lymphoma. Results We recruited 10 patients with R/R B-cell lymphoma undergoing CXCR5 CD19 CAR-T cells therapy. The objective response rate was 80%, complete response rate was 50%. The progression-free survival of these ten patients was 5 months (95% CI 1.02-8.98 months), while the median overall survival was 17.76 months (95% CI 13.54-21.98 months). The incidence of grade 1 and grade 2 cytokine release syndrome (CRS) was 70% and 20%, respectively. No patient experienced grade 3 or higher level of CRS, neurotoxicity and infusion-related dose toxicity. Conclusions In this study, we suggest that the results obtained here can pave the way for CXCR5 CD19 CAR-T cells to be investigated in a trial with broader patient populations. Trial registration The trials were registered at www.chictr.org.cn as ChiCTR2100052677 and ChiCTR1900028692." @default.
• W4315702793 created "2023-01-12" @default.
• W4315702793 creator A5010330473 @default.
• W4315702793 creator A5012766223 @default.
• W4315702793 creator A5017005333 @default.
• W4315702793 creator A5019573444 @default.
• W4315702793 creator A5026513884 @default.
• W4315702793 creator A5034649465 @default.
• W4315702793 creator A5037341948 @default.
• W4315702793 creator A5044110703 @default.
• W4315702793 creator A5050809443 @default.
• W4315702793 creator A5054816608 @default.
• W4315702793 creator A5055051950 @default.
• W4315702793 creator A5070543187 @default.
• W4315702793 creator A5074140059 @default.
• W4315702793 creator A5077931358 @default.
• W4315702793 date "2023-01-12" @default.
• W4315702793 modified "2023-10-18" @default.
• W4315702793 title "Phase I clinical trial of CD19 CAR-T cells expressing CXCR5 protein for the treatment of relapsed or refractory B-cell lymphoma" @default.
• W4315702793 cites W1600643972 @default.
• W4315702793 cites W1989112363 @default.
• W4315702793 cites W2020789296 @default.
• W4315702793 cites W2053303373 @default.
• W4315702793 cites W2078849072 @default.
• W4315702793 cites W2121099202 @default.
• W4315702793 cites W2131525061 @default.
• W4315702793 cites W2138386266 @default.
• W4315702793 cites W2497442705 @default.
• W4315702793 cites W2596972789 @default.
• W4315702793 cites W2612307934 @default.
• W4315702793 cites W2633419294 @default.
• W4315702793 cites W2744261860 @default.
• W4315702793 cites W2898272383 @default.
• W4315702793 cites W2940883995 @default.
• W4315702793 cites W2951928294 @default.
• W4315702793 cites W2966873510 @default.
• W4315702793 cites W2976192812 @default.
• W4315702793 cites W2982579556 @default.
• W4315702793 cites W3006502736 @default.
• W4315702793 cites W3011877367 @default.
• W4315702793 cites W3037222433 @default.
• W4315702793 cites W3039162285 @default.
• W4315702793 cites W3093627928 @default.
• W4315702793 cites W3095855647 @default.
• W4315702793 cites W3123979179 @default.
• W4315702793 cites W3179112978 @default.
• W4315702793 cites W3185183014 @default.
• W4315702793 cites W3203617810 @default.
• W4315702793 cites W4206468380 @default.
• W4315702793 cites W4220820993 @default.
• W4315702793 doi "https://doi.org/10.21203/rs.3.rs-2459480/v1" @default.
• W4315702793 hasPublicationYear "2023" @default.
• W4315702793 type Work @default.
• W4315702793 citedByCount "0" @default.
• W4315702793 crossrefType "posted-content" @default.
• W4315702793 hasAuthorship W4315702793A5010330473 @default.
• W4315702793 hasAuthorship W4315702793A5012766223 @default.
• W4315702793 hasAuthorship W4315702793A5017005333 @default.
• W4315702793 hasAuthorship W4315702793A5019573444 @default.
• W4315702793 hasAuthorship W4315702793A5026513884 @default.
• W4315702793 hasAuthorship W4315702793A5034649465 @default.
• W4315702793 hasAuthorship W4315702793A5037341948 @default.
• W4315702793 hasAuthorship W4315702793A5044110703 @default.
• W4315702793 hasAuthorship W4315702793A5050809443 @default.
• W4315702793 hasAuthorship W4315702793A5054816608 @default.
• W4315702793 hasAuthorship W4315702793A5055051950 @default.
• W4315702793 hasAuthorship W4315702793A5070543187 @default.
• W4315702793 hasAuthorship W4315702793A5074140059 @default.
• W4315702793 hasAuthorship W4315702793A5077931358 @default.
• W4315702793 hasBestOaLocation W43157027931 @default.
• W4315702793 hasConcept C126322002 @default.
• W4315702793 hasConcept C12823836 @default.
• W4315702793 hasConcept C13373296 @default.
• W4315702793 hasConcept C143998085 @default.
• W4315702793 hasConcept C159654299 @default.
• W4315702793 hasConcept C170493617 @default.
• W4315702793 hasConcept C203014093 @default.
• W4315702793 hasConcept C2776090121 @default.
• W4315702793 hasConcept C2776708503 @default.
• W4315702793 hasConcept C2778957590 @default.
• W4315702793 hasConcept C2779338263 @default.
• W4315702793 hasConcept C2780850621 @default.
• W4315702793 hasConcept C3875195 @default.
• W4315702793 hasConcept C502942594 @default.
• W4315702793 hasConcept C535046627 @default.
• W4315702793 hasConcept C71924100 @default.
• W4315702793 hasConcept C75877943 @default.
• W4315702793 hasConcept C8891405 @default.
• W4315702793 hasConceptScore W4315702793C126322002 @default.
• W4315702793 hasConceptScore W4315702793C12823836 @default.
• W4315702793 hasConceptScore W4315702793C13373296 @default.
• W4315702793 hasConceptScore W4315702793C143998085 @default.
• W4315702793 hasConceptScore W4315702793C159654299 @default.
• W4315702793 hasConceptScore W4315702793C170493617 @default.
• W4315702793 hasConceptScore W4315702793C203014093 @default.
• W4315702793 hasConceptScore W4315702793C2776090121 @default.
• W4315702793 hasConceptScore W4315702793C2776708503 @default.
• W4315702793 hasConceptScore W4315702793C2778957590 @default.
• W4315702793 hasConceptScore W4315702793C2779338263 @default.
• W4315702793 hasConceptScore W4315702793C2780850621 @default.

• next